Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Gastroenterology|September 30, 2018
Hdac1 Regulates Differentiation of Bipotent Liver Progenitor Cells During Regeneration via Sox9b and Cdk8Sungjin Ko, Jacquelyn O Russell, Jianmin Tian, et al.
Hepatology (Baltimore, Md.)|March 8, 2022
A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditionsRilu Feng, Kejia Kan, Carsten Sticht, et al.
Hepatology Communications|July 18, 2024
Retinoic acid generates a beneficial microenvironment for liver progenitor cell activation in acute liver failureSai Wang, Frederik Link, Stefan Munker, et al.
Journal of Autoimmunity|June 6, 2024
Prevalence and clinical profiles of primary sclerosing cholangitis in China: Data from electronic medical records and systematic literature retrievalXiaoqian Xu, Tongtong Meng, Lichen Shi, et al.
Clinical and Molecular Hepatology|May 11, 2023
Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patientsXiaoning Wu, Xiaoqian Xu, Jialing Zhou, et al.
Journal of Clinical and Translational Hepatology|February 9, 2026
Chinese Guidelines for Clinical Diagnosis, Treatment, and Management of Cirrhosis (2025)Xiaoyuan Xu, Huiguo Ding, Hong You, et al.
Hepatology International|August 19, 2023
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosisYuanyuan Kong, Yameng Sun, Xiaoning Wu, et al.
Radiology|November 21, 2018
Virtual Hepatic Venous Pressure Gradient with CT Angiography (CHESS 1601): A Prospective Multicenter Study for the Noninvasive Diagnosis of Portal HypertensionXiaolong Qi, Weimin An, Fuquan Liu, et al.
Infection and Drug Resistance|April 25, 2019
Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort studyXiaoning Wu, Jialing Zhou, Wen Xie, et al.
BMC Gastroenterology|November 20, 2020
Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trialJieting Tang, Yongfeng Wang, Tao Han, et al.
Pageof 11